On March 11, The European Medicines Agency (EMA) cited3 30 cases of thrombotic events among almost 5 million people in the European Economic Area who had the AstraZeneca vaccine.
In their latest statement, EMA said the benefits of AstraZeneca, now called Vaxevria, continue to outweigh the risks in all age groups. However, “very rare cases” of blood clotting with low platelet count may occur after vaccination.
WHO: No association between thrombotic incidences and AstraZeneca vaccine
On March 16, the World Health Organization’s chief scientist, Soumya Swaminathan, emphasized4 that, so far, they do not see a connection between the potential blood clots side-effects and the AstraZeneca vaccine.
For this reason, they urge the countries not to halt their vaccine rollout.
To date, Thailand has announced that they will be pushing through with their vaccination program using AstraZeneca despite delaying it before due to safety concerns. Indonesia, on the other hand, delayed its rollout until further notice.
AstraZeneca: “The number of thrombotic incidences was small.”
AstraZeneca continues to assure the people of their vaccine’s safety based on “clear scientific evidence.” The data they gathered from 200 million people who received the vaccine also showed that the occurrences of blood clots with low platelet are “very rare.”
Despite this, the company behind AstraZeneca believes that the safety of the public should always come first; hence, they are keeping the issue under close review.
In their most recent post, AstraZeneca said that regulating agencies see a connection between the vaccine and blood clots with low platelet. For this reason, the agencies requested them to list the incidence as an “extremely rare potential side-effect.”